Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. - Wikidata - awgldk - TriplyDB

Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.

Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.

http://www.wikidata.org/entity/Q34762427

about

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 Structure-based design and synthesis of a bivalent iminobiotin analog showing strong affinity toward a low immunogenic streptavidin mutant Structure-based design of a streptavidin mutant specific for an artificial biotin analogue Radioimmunotherapy of human tumours Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs.Success of measles virotherapy in ATL depends on type I interferon secretion and responsiveness.Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.Pretargeted radioimmunotherapy for hematologic and other malignancies Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.The potential and hurdles of targeted alpha therapy - clinical trials and beyond.Radioimmunotherapy with α-particle-emitting radionuclides.Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma Measles virotherapy in a mouse model of adult T-cell leukaemia/lymphoma Conscripts of the infinite armada: systemic cancer therapy using nanomaterials.Antibody-based treatment of acute myeloid leukaemia.ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters.(212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25 Adult T cell leukemia lymphoma.124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.Human T cell lymphotropic virus-associated leukemia/lymphoma Tailoring antibodies for radionuclide delivery.Advances in radioimmunotherapy in the age of molecular engineering and pretargeting.Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.Targeted alpha-therapy: past, present, future?Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.A versatile bifunctional dendritic cell targeting vaccine vector A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.Advances in the treatment of hematologic malignancies using immunoconjugates Radioimmunotherapy for hematopoietic cell transplantation.Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus.Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia.Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery.

P2860

Q24629826-3C117231-C049-43E0-8199-56FEBC0751DA Q24685212-A8D12DC3-AD91-4CF6-B0F2-E6E752785E42 Q27697299-6C65114E-2EF8-4CE7-BA85-869763F9F0ED Q27697883-7CE9C4FF-0FBD-482F-9EF7-4761141BB5A0 Q28088825-A8EDF5A2-AB55-492C-8343-C36C26C944F2 Q31085503-FAA77963-48CD-4EEC-A1FC-426B2F7AED9E Q34053730-39A29A8A-A615-4324-B600-A75BBED59CEF Q34077332-7E51898D-1EAE-43D2-8B90-22C172EF8EC2 Q34113941-1AD4921E-150A-42EF-A663-B01CE98A47A0 Q34360360-7E233948-891C-4AD8-B0F0-0FCE5785DD33 Q34399879-642924B8-30A3-46E8-A756-4497FE54EF90 Q34419562-3E7A1507-8D1E-463F-BB15-EE9FBC53EC2B Q35059542-47ED081E-2036-4587-8125-20E1AB41BE42 Q35200122-1B4DF2B4-E7D0-4AAB-AD7A-208832745A9B Q35545342-44694CC4-E523-4B22-9875-8D828B4CDB93 Q35609792-B9A55480-E374-4DF2-990F-82558A71E239 Q35808435-F51406DB-05A5-4CFB-8B46-F1E18D77B102 Q35815494-9DCB0CEB-1BBC-4ED5-B6D9-43C3108DA039 Q35849837-05877E61-00BB-4037-BC7B-53D6EAE78B0C Q35849893-D6AA3C80-21F3-4BB0-9A68-76EB10D3B21C Q35880693-9DBD6D79-B0F9-4B71-8B56-B2C9B9F44AAD Q36088136-7F3C5312-6671-4427-B10A-1478ADD4AA6F Q36225607-B278AC8C-2728-4AB9-934F-E262DB2BDA8E Q36349687-12240BEE-4AF5-4EC1-995D-7D698BA38B3C Q36391426-1D8B5B1C-C1F6-4681-B106-9E0246C48F1C Q36395999-1EB03BB9-1C47-4776-B6EF-0C0F98AA8ABB Q36445890-CAC2EBD2-2D8E-46D9-82EC-08D32DFE135F Q36691184-EFA53AF0-B8E9-4D4A-B5DE-113276F8F069 Q37036289-DAB1C408-C909-4669-B5B6-6B338D49EEAE Q37183994-7EFB382C-C12A-404C-90F7-F52F17E1AACA Q37201878-EAAFAD2A-3AA1-4DA2-9965-4BB5FC33EDB7 Q37295150-B5689F11-454A-4FEE-8BFC-C45491861607 Q37412334-E2EB26CD-7643-4DE7-91AD-8FD442B04695 Q37697843-71B5E5D1-99C5-4C19-B057-B8B4A359EE6D Q38096058-DA577B45-0A2E-4F85-97DE-26FA514D3944 Q40479713-D4307373-5A98-409D-8938-28305B7850B5 Q47435794-07C71FC1-0EB7-43F1-A696-09B5C5145006 Q48298566-A6F5B929-C5F8-4E92-A0E2-2D14AB869A48

P2860

Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.

http://www.wikidata.org/entity/Q34762427

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Pretarget radiotherapy with an ...... leukemia/lymphoma xenografts.

@ast

Pretarget radiotherapy with an ...... leukemia/lymphoma xenografts.

@en

Pretarget radiotherapy with an ...... leukemia/lymphoma xenografts.

@nl

type

label

Pretarget radiotherapy with an ...... leukemia/lymphoma xenografts.

@ast

Pretarget radiotherapy with an ...... leukemia/lymphoma xenografts.

@en

Pretarget radiotherapy with an ...... leukemia/lymphoma xenografts.

@nl

prefLabel

Pretarget radiotherapy with an ...... leukemia/lymphoma xenografts.

@ast

Pretarget radiotherapy with an ...... leukemia/lymphoma xenografts.

@en

Pretarget radiotherapy with an ...... leukemia/lymphoma xenografts.

@nl

P1433

Q34762427-B5CC6931-2362-4566-926D-F14257A4EBD2

P1476

Q34762427-89307500-D22F-477E-9C79-4152044D422B

P2093

Q34762427-007050A6-533D-4772-9EE6-DC06F938FCF6

Q34762427-1614A078-1DAF-4477-AEB9-B353FCB8FF39

Q34762427-68CE772D-C0D2-4B57-937F-D59575273B49

Q34762427-78E513F3-F15F-4B51-8B6C-04668A0E1B89

Q34762427-97E906D1-B218-47EF-B8A6-F66583A2FD32

Q34762427-9C14158C-82C1-4300-8CDE-3F42C41252B8

Q34762427-9C798A5F-69F2-4A46-9272-E27A8D353354

Q34762427-D4C467A1-D8D6-4FBE-BE14-10EF0FA59FC9

P2860

Q34762427-0B9FA452-9225-4714-8ED7-E9EE0BAB4A27

Q34762427-0CCDCCB4-EDE0-4894-81C7-1C5021B049A4

Q34762427-17DF4D21-2AC5-44EB-80E8-2ACCF4BAAE2D

Q34762427-2B60820C-11FA-4D16-8651-16F49CCE406E

Q34762427-370463CF-6209-4A3D-8A47-BE9B7044CC25

Q34762427-3BE03C7C-83C2-4B54-8179-8925E8E80295

Q34762427-3D8271A1-395B-49F9-8958-846B17A305AE

Q34762427-42710432-ABC6-4D1C-B5FF-AA6456DCB24C

Q34762427-49047A44-3532-4038-9EEB-80F89C9B6CF8

Q34762427-4DF8C0A6-DF6B-45F9-A2B4-127B77E772BE

P304

Q34762427-A4C58B07-BC9F-4E5C-8A69-74456638BE68

P31

Q34762427-E54060C5-213A-4D29-80B9-EC06E35E92AD

P356

Q34762427-31BDBAF6-07CF-444D-96F6-324260ACE225

P407

Q34762427-80D08EB3-8F97-45A5-A6A0-9F823443F7C6

P433

Q34762427-ED45BF7D-6403-4F82-A94B-ABF46ED3F647

P478

Q34762427-677AAE29-61F5-484C-A67C-ECE8794068B9

P50

Q34762427-30E6860C-B9D1-4A37-A560-A5BAE23B9061

P577

Q34762427-23041B50-9DF1-4487-95C4-412DFBD19BA7

P5875

Q34762427-0F96FCFD-7CD4-4AC7-921A-E99096B3708C

P698

Q34762427-0FB871AD-1228-447F-815A-33D9AE8E1185

P921

Q34762427-02CB077A-DA93-4856-9431-0D856AFFA773

Q34762427-3644559C-E24A-4CDF-B2B5-00E731E21DDF

Q34762427-6189352B-8E04-435D-849F-8FDC86EC3137

Q34762427-62A4D246-CFC3-4131-8C51-594532B0942E

P932

Q34762427-4E37B586-6D07-46BE-8603-A73F8BAF1D59

P356

PNAS.0437788100

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Pretarget radiotherapy with an ...... leukemia/lymphoma xenografts.

@en

P2093

Carolyn K Goldman

http://www.w3.org/2001/XMLSchema#string

Donald B Axworthy

http://www.w3.org/2001/XMLSchema#string

Jody Schultz

http://www.w3.org/2001/XMLSchema#string

Kayhan Garmestani

http://www.w3.org/2001/XMLSchema#string

Martin W Brechbiel

http://www.w3.org/2001/XMLSchema#string

Meili Zhang

http://www.w3.org/2001/XMLSchema#string

Thomas A Waldmann

http://www.w3.org/2001/XMLSchema#string

Zhuo Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

A humanized antibody that binds to the interleukin 2 receptor

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

Tumor therapy with targeted atomic nanogenerators.

The multichain interleukin-2 receptor: a target for immunotherapy.

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.

Overview of studies on experimental radioimmunotherapy.

Pharmacokinetics of high molecular weight agents.

Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.

Preclinical evaluation of 111In-labeled B3 monoclonal antibody: biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts.

P304

1891-1895

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0437788100

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Jorge A. Carrasquillo

P577

2003-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10916337

http://www.w3.org/2001/XMLSchema#string

P698

12569172

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

149929

http://www.w3.org/2001/XMLSchema#string